Skip to main content

Table 2 Chemotherapies and endocrine therapies for the treatment of recurrent breast cancer for the two cohorts

From: Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000

  Cohort A
(n = 170)
Cohort B
(n = 237)
Therapy No. of Patients % No. of Patients %
Hormone therapy, %     
   Tamoxifen 65 38* 62 26
   Medroxyprogesterone acetate 80 47* 35 15
   Aromatase inhibitors 19 11* 130 55
Chemotherapy, %     
   Anthracyclines 81 48* 51 22
   Taxanes 43 25* 110 46
   Vinorelbine 4 2.4* 60 25
   Capecitabine 13 7.6* 100 42
   Mitomycin 82 49* 2 0.8
HER2 targeting therapy, %     
   Trastuzumab 5 2.9* 51 22
  1. *P < .05